pioglitazone has been researched along with Acute Liver Injury, Drug-Induced in 49 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Liver failure associated with rosiglitazone or pioglitazone was defined as liver injury accompanied by hepatic encephalopathy, liver transplantation, placement on a liver transplant list, or death in which all other likely etiologies were excluded." | 7.75 | Case series of liver failure associated with rosiglitazone and pioglitazone. ( Barbehenn, E; Floyd, JS; Lurie, P; Wolfe, SM, 2009) |
| "The aim of this study was to assess the incidence of liver failure in association with antidiabetic treatment using pioglitazone vs." | 7.73 | Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. ( Iyer, S; Perez, A; Rajagopalan, R, 2005) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 6.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| " Liver failure associated with rosiglitazone or pioglitazone was defined as liver injury accompanied by hepatic encephalopathy, liver transplantation, placement on a liver transplant list, or death in which all other likely etiologies were excluded." | 3.75 | Case series of liver failure associated with rosiglitazone and pioglitazone. ( Barbehenn, E; Floyd, JS; Lurie, P; Wolfe, SM, 2009) |
| "The aim of this study was to assess the incidence of liver failure in association with antidiabetic treatment using pioglitazone vs." | 3.73 | Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. ( Iyer, S; Perez, A; Rajagopalan, R, 2005) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 2.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| " This is further supported by experimental data that demonstrate that troglitazone, alone among the thiazolidinediones, is toxic in hepatocyte cell culture." | 2.42 | Hepatotoxicity of the thiazolidinediones. ( Chandramouli, J; Tolman, KG, 2003) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular complications." | 2.41 | Hepatotoxicity with thiazolidinediones: is it a class effect? ( Scheen, AJ, 2001) |
| "Tamoxifen (TAM) is a chemotherapeutic drug widely utilized to treat breast cancer." | 1.91 | Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis. ( Elariny, HA; Kamel, GAM, 2023) |
| "Acetaminophen has a reasonable safety profile when consumed in therapeutic doses." | 1.40 | Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats. ( Candasamy, M; Chellappan, DK; Dua, K; Gubbiyappa, KS; Gupta, G; Krishna, G, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7." | 1.37 | Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. ( Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "Troglitazone is a thiazolidinedione insulin sensitizer drug that is metabolized mainly to a sulfate conjugate (M-1) in humans." | 1.32 | Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. ( Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T, 2004) |
| "Pioglitazone was promptly discontinued because her symptoms were consistent with those of hepatic dysfunction and pioglitazone was identified as a potential cause." | 1.32 | Second-generation thiazolidinediones and hepatotoxicity. ( Blevins, SM; Britton, ML; Marcy, TR, 2004) |
| "Pioglitazone prevented increase in plasma aspartate transaminase, alanine aminotransferase, and TNF-alpha levels but had no effect on plasma and hepatic levels of lipid peroxide." | 1.32 | Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. ( Hashimoto, K; Hokkyo, K; Nakajima, H; Ohata, M; Sakamoto, K; Suzuki, H; Toda, G; Yamada, H; Yamauchi, M, 2004) |
| "Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class." | 1.31 | Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. ( Kram, MT; Lefkowitch, JH; May, LD; Rubin, DE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (59.18) | 29.6817 |
| 2010's | 18 (36.73) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Nozawa, T | 1 |
| Sugiura, S | 1 |
| Nakajima, M | 1 |
| Goto, A | 1 |
| Yokoi, T | 1 |
| Nezu, J | 1 |
| Tsuji, A | 1 |
| Tamai, I | 1 |
| Yamamoto, K | 1 |
| Itoh, T | 1 |
| Abe, D | 1 |
| Shimizu, M | 1 |
| Kanda, T | 1 |
| Koyama, T | 1 |
| Nishikawa, M | 1 |
| Tamai, T | 1 |
| Ooizumi, H | 1 |
| Yamada, S | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Dawson, S | 1 |
| Stahl, S | 2 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Aleo, MD | 1 |
| Luo, Y | 1 |
| Swiss, R | 1 |
| Bonin, PD | 1 |
| Potter, DM | 1 |
| Will, Y | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Norman, BH | 1 |
| Kamel, GAM | 1 |
| Elariny, HA | 1 |
| Chang, JH | 1 |
| Sangaraju, D | 1 |
| Liu, N | 1 |
| Jaochico, A | 1 |
| Plise, E | 1 |
| Meng, YK | 1 |
| Li, CY | 1 |
| Li, RY | 1 |
| He, LZ | 1 |
| Cui, HR | 1 |
| Yin, P | 1 |
| Zhang, CE | 1 |
| Li, PY | 1 |
| Sang, XX | 1 |
| Wang, Y | 1 |
| Niu, M | 1 |
| Zhang, YM | 1 |
| Guo, YM | 1 |
| Sun, R | 1 |
| Wang, JB | 1 |
| Bai, ZF | 1 |
| Xiao, XH | 1 |
| Mak, A | 1 |
| Kato, R | 1 |
| Weston, K | 1 |
| Hayes, A | 1 |
| Uetrecht, J | 1 |
| Gupta, G | 1 |
| Krishna, G | 1 |
| Chellappan, DK | 1 |
| Gubbiyappa, KS | 1 |
| Candasamy, M | 1 |
| Dua, K | 1 |
| Floyd, JS | 1 |
| Barbehenn, E | 1 |
| Lurie, P | 1 |
| Wolfe, SM | 1 |
| Osei, SY | 1 |
| Koro, CE | 1 |
| Cobitz, AR | 1 |
| Kolatkar, NS | 1 |
| Stender, M | 1 |
| Tolman, KG | 2 |
| Freston, JW | 2 |
| Kupfer, S | 1 |
| Perez, A | 2 |
| Beiderbeck, AB | 1 |
| Sakaguchi, M | 1 |
| Berthet, S | 1 |
| Olivier, P | 1 |
| Montastruc, JL | 1 |
| Lapeyre-Mestre, M | 1 |
| Chojkier, M | 1 |
| Elkhayat, H | 1 |
| Sabry, D | 1 |
| Donohue, M | 1 |
| Buck, M | 1 |
| Kawamori, R | 2 |
| Kobayashi, M | 3 |
| Iwata, M | 3 |
| Hiratani, K | 1 |
| Kaplowitz, N | 1 |
| Lewis, JH | 1 |
| Watkins, PB | 1 |
| Hisamochi, A | 1 |
| Kumashiro, R | 1 |
| Koga, Y | 1 |
| Tanaka, E | 1 |
| Ide, T | 1 |
| Hino, T | 1 |
| Murashima, S | 1 |
| Ogata, K | 1 |
| Kuwahara, R | 1 |
| Koga, H | 1 |
| Shishido, S | 1 |
| Ueno, T | 1 |
| Sata, M | 1 |
| Eguchi, T | 1 |
| Chandramouli, J | 1 |
| Marcy, TR | 1 |
| Britton, ML | 1 |
| Blevins, SM | 1 |
| Ohata, M | 1 |
| Suzuki, H | 1 |
| Sakamoto, K | 1 |
| Hashimoto, K | 1 |
| Nakajima, H | 1 |
| Yamauchi, M | 1 |
| Hokkyo, K | 1 |
| Yamada, H | 1 |
| Toda, G | 1 |
| Amin, P | 1 |
| Rajagopalan, R | 1 |
| Iyer, S | 1 |
| Slavin, DE | 1 |
| Schlichting, CL | 1 |
| Enomoto, N | 1 |
| Takei, Y | 1 |
| Yamashima, S | 1 |
| Ikejima, K | 1 |
| Kitamura, T | 1 |
| Sato, N | 1 |
| Da Silva Morais, A | 1 |
| Abarca-Quinones, J | 1 |
| Horsmans, Y | 1 |
| Stärkel, P | 1 |
| Leclercq, IA | 1 |
| Martínez Odriozola, P | 1 |
| Ibarmia Lahuerta, J | 1 |
| Gutiérrez Macías, A | 1 |
| de la Villa, FM | 1 |
| Kanazawa, A | 1 |
| Haruta, T | 1 |
| Krentz, AJ | 1 |
| Bailey, CJ | 1 |
| Melander, A | 1 |
| Gale, EA | 1 |
| Maeda, K | 1 |
| Scheen, AJ | 1 |
| May, LD | 1 |
| Lefkowitch, JH | 1 |
| Kram, MT | 1 |
| Rubin, DE | 1 |
| Nierenberg, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl vs Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes[NCT00494312] | Phase 4 | 2,120 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975] | Phase 2 | 0 participants (Actual) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was completed in another site) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for pioglitazone and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Eval | 2020 |
[Pioglitazone].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglyce | 2002 |
Hepatotoxicity of the thiazolidinediones.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; | 2003 |
[Adverse effects of insulin sensitisers and biguanides].
Topics: Acidosis, Lactic; Animals; Biguanides; Capillary Permeability; Chemical and Drug Induced Liver Injur | 2007 |
[Clinical evaluation of pioglitazone].
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; G | 2000 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes | 2001 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, | 2001 |
2 trials available for pioglitazone and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Chemical and Drug Induced Liver Injury; D | 2009 |
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G | 2012 |
38 other studies available for pioglitazone and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Topics: Biological Transport, Active; Chemical and Drug Induced Liver Injury; Chromans; Cloning, Molecular; | 2004 |
Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents.
Topics: Animals; Binding Sites; Chemical and Drug Induced Liver Injury; COS Cells; Diabetes Mellitus, Experi | 2005 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2014 |
Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis.
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Inflammation; Kelch-Like ECH-Associat | 2023 |
Comprehensive Evaluation of Bile Acid Homeostasis in Human Hepatocyte Co-Culture in the Presence of Troglitazone, Pioglitazone, and Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Acids and Salts; Cells, Cultured; Chemical an | 2019 |
Cis-stilbene glucoside in Polygonum multiflorum induces immunological idiosyncratic hepatotoxicity in LPS-treated rats by suppressing PPAR-γ.
Topics: Animals; Chemical and Drug Induced Liver Injury; Emodin; Fallopia multiflora; Glucosides; Lipopolysa | 2017 |
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
Topics: Animals; Antibodies, Monoclonal; Catechols; Cell Line; Chemical and Drug Induced Liver Injury; CTLA- | 2018 |
Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Lipid Peroxidation; Pioglitazone; PP | 2014 |
Case series of liver failure associated with rosiglitazone and pioglitazone.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Chemical and Drug Induced Liver Injury; Databases, Fa | 2009 |
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, | 2009 |
Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, | 2009 |
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; | 2011 |
[Biguanide, pioglitazone and alpha-glucosidase inhibitors].
Topics: Acidosis, Lactic; Biguanides; Body Weight; Chemical and Drug Induced Liver Injury; Digestive System; | 2012 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type | 2002 |
Did this drug cause my patient's hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postma | 2003 |
[A case of drug induced liver injury related pioglitazone].
Topics: Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Diab | 2003 |
Second-generation thiazolidinediones and hepatotoxicity.
Topics: Adult; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem | 2004 |
Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha.
Topics: Animals; Chemical and Drug Induced Liver Injury; Ethanol; Female; Lipopolysaccharides; Liver Disease | 2004 |
Liver toxicity and pioglitazone: data are missing.
Topics: Chemical and Drug Induced Liver Injury; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedione | 2004 |
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver In | 2005 |
Rating the severity of the medical consequences of drug-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Humans; Hypoglycemic Agents; Live | 2005 |
Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization.
Topics: Animals; Chemical and Drug Induced Liver Injury; Endotoxins; Enzyme-Linked Immunosorbent Assay; Fema | 2005 |
Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
Topics: Animals; Carbon Tetrachloride; Cells, Cultured; Chemical and Drug Induced Liver Injury; Extracellula | 2007 |
[A new case: pioglitazone hepatotoxicity].
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazo | 2007 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug | 2000 |
Hepatocellular injury in a patient receiving pioglitazone.
Topics: Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2001 |
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Typ | 2002 |
"Did this drug cause my patient's hepatitis?" and related questions.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inte | 2002 |
Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Typ | 2002 |